

Which intravenous fluid should be given for hospitalized patients?: A prospective randomised study

Submission date

14/05/2007

Recruitment status

No longer recruiting

Registration date

28/09/2007

Overall study status

Completed

Last Edited

10/03/2008

Condition category

Nutritional, Metabolic, Endocrine

☐ Prospectively registered

☐ Protocol

☐ Statistical analysis plan

☐ Results

☐ Individual participant data

☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Metin Karaböcöğlu

Contact details

Istanbul University

Istanbul Faculty of Medicine

Department of Paediatric Intensive Care

Millet Cad

Fındıkzade

Istanbul

Türkiye

34390

+01190 5332341818

mkara63@hotmail.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Study objectives

The hypothesis of the study is that in sick children, moderately hypotonic fluids (such as fluids contain 77 mmol/L sodium) are better tolerated (i.e. induce less hyponatraemia without the risk of hypernatraemia) than conventional intravenous fluids that contain 34 mmol/L sodium.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical Board of Istanbul University, Istanbul Faculty of Medicine, approved on 13 June 2005.

Ref: 2005/526.

Study design

Randomized controlled trial.

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Hyponatraemia

Interventions

The patients were randomized to one of the three study arms prospectively. Stratified block randomization was performed, with each one-week block featuring a different intravenous solution. Randomization was performed separately for children on the ward and children in the Paediatric Intensive Care Unit (PICU).

Arm 1: 0.2% sodium in 5% dextrose

Arm 2: 0.3% sodium in 3.3% dextrose

Arm 3: 0.45% sodium in 5% dextrose

When hyponatraemia developed in any group during the therapy intravenous fluid sodium composition was increased and fluid therapy was decreased to 80% of the initial volume.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Intravenous Fluid

Primary outcome measure

Association between administration of hypotonic fluids and hospital-acquired hyponatraemia, assessed by the following:

1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24

Secondary outcome measures

To determine contributive factors that may increase hyponatraemia risk, assessed by the following:

1. Plasma sodium, potassium and osmolality in all blood samples collected at admission (T0) and 12 (T12), 24 (T24), 48 (T48) and 72 (T72) hours of intravenous fluids therapy.
2. Plasma urea, creatinine and uric acid, measured in all blood samples collected at T0 and T24.
3. Plasma AntiDiuretic Hormone (ADH), measured at T0. Abnormal ADH function was assessed by serum osmolality and serum sodium determinations.

Overall study start date

15/06/2005

Completion date

26/05/2006

Eligibility

Key inclusion criteria

All children aged between 3 months to 16 years old who received intravenous fluids

Participant type(s)

Patient

Age group

Child

Lower age limit

3 Months

Upper age limit

16 Years

Sex

Not Specified

Target number of participants

100

Key exclusion criteria

1. Dehydration
2. Cerebral oedema
3. Nephrotic syndrome
4. Hepatorenal syndrome
5. Plasma sodium level below 135 mmol/L
6. Congestive heart failure
7. Renal failure
8. Inborn error of metabolism
9. Protein energy malnutrition
10. Patients receiving mannitol or diuretics
11. Patients whose fluid therapy was started before admission

Date of first enrolment

15/06/2005

Date of final enrolment

26/05/2006

Locations**Countries of recruitment**

Türkiye

Study participating centre

Istanbul University

Istanbul

Türkiye

34390

Sponsor information**Organisation**

Istanbul University, Faculty of Medicine (Turkey)

Sponsor details

Department of Paediatric Intensive Care

Millet Cad

Fındıkzade

Istanbul
Türkiye
34390

Sponsor type
University/education

ROR
<https://ror.org/03a5qrr21>

Funder(s)

Funder type
Other

Funder Name
Mainly investigator-funded with support from Ege Medical Company (Turkey)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration